News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
11,243 Results
Type
Article (272)
Company Profile (1)
Press Release (10970)
Section
Business (6867)
Career Advice (4)
Deals (817)
Drug Delivery (1)
Drug Development (850)
FDA (104)
Job Trends (240)
News (7734)
Policy (196)
Tag
2027 Biotech Bay Standard (1)
Academia (12)
Accelerated approval (1)
Allergies (6)
Alliances (119)
ALS (3)
Alzheimer's disease (14)
Antibody-drug conjugate (ADC) (9)
Approvals (124)
Artificial intelligence (7)
ASCO (8)
Autoimmune disease (11)
Bankruptcy (3)
Belgium (2)
Best Places to Work (228)
Biologics (1)
Biosimilars (4)
BioSpace Insights (1)
Bispecific (1)
Bladder cancer (4)
Brain cancer (3)
Breast cancer (15)
Cancer (121)
Cardiovascular disease (15)
Career advice (5)
Career pathing (1)
CAR-T (8)
CDMO (2)
Celiac Disease (1)
Cell therapy (23)
Cervical cancer (1)
Clinical research (913)
Collaboration (21)
Commercialization (2)
Compensation (18)
Complete response letters (4)
COVID-19 (17)
CRISPR (2)
C-suite (2)
Cystic fibrosis (7)
Data (265)
Depression (3)
Dermatology (5)
Diabetes (14)
Diagnostics (131)
Drug discovery (3)
Drug pricing (1)
Duchenne muscular dystrophy (3)
Earnings (7756)
ESMO (8)
Events (559)
Executive appointments (3)
FDA (247)
Friedreich's ataxia (1)
Funding (11)
Gene editing (3)
Generative AI (2)
Gene therapy (11)
GLP-1 (14)
Government (21)
Guidances (89)
Healthcare (321)
Hematology (6)
HIV (5)
IgA nephropathy (1)
Immunology and inflammation (6)
Immuno-oncology (2)
Indications (5)
Infectious disease (21)
Inflammatory bowel disease (1)
Influenza (2)
Intellectual property (3)
IPO (725)
Job creations (25)
Job search strategy (4)
JPM (1)
Kidney disease (2)
Labor market (3)
Layoffs (12)
Leadership (1)
Legal (25)
Licensing (1)
Lung cancer (26)
Lymphoma (13)
Machine learning (1)
Manufacturing (11)
Marketing (1)
MASH (6)
Medical device (367)
Medtech (379)
Mergers & acquisitions (104)
Metabolic disorders (25)
mRNA (3)
Multiple sclerosis (8)
Netherlands (2)
Neurodegenerative disease (1)
Neuroscience (39)
NextGen: Class of 2026 (84)
Non-profit (24)
Obesity (7)
Ovarian cancer (1)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (6)
Partnered (1)
Patient recruitment (5)
Peanut (2)
People (106)
Peptides (1)
Pharmacy benefit managers (1)
Phase 1 (211)
Phase 2 (369)
Phase 3 (405)
Pipeline (783)
Postmarket research (37)
Preclinical (39)
Prostate cancer (4)
Radiopharmaceuticals (3)
Rare diseases (26)
Real estate (11)
Regenerative medicine (1)
Regulatory (227)
Reports (4)
Research institute (12)
Rett syndrome (1)
RSV (1)
Schizophrenia (2)
Series A (1)
Series B (1)
Special edition (1)
Startups (17)
Stomach cancer (1)
Switzerland (1)
Vaccines (8)
Weight loss (5)
Women's health (3)
Worklife (1)
Date
Today (23)
Last 7 days (64)
Last 30 days (174)
Last 365 days (872)
2026 (810)
2025 (837)
2024 (908)
2023 (993)
2022 (1238)
2021 (1118)
2020 (925)
2019 (620)
2018 (573)
2017 (415)
2016 (222)
2015 (382)
2014 (243)
2013 (152)
2012 (175)
2011 (209)
2010 (237)
Location
Africa (6)
Alabama (2)
Arizona (10)
Asia (623)
Australia (61)
California (458)
Canada (95)
China (31)
Colorado (21)
Connecticut (28)
Delaware (21)
Europe (1393)
Florida (75)
Georgia (19)
Illinois (32)
India (1)
Indiana (21)
Japan (9)
Kansas (2)
Kentucky (1)
Louisiana (9)
Maine (3)
Maryland (62)
Massachusetts (277)
Michigan (14)
Minnesota (20)
Missouri (2)
Nevada (3)
New Hampshire (4)
New Jersey (136)
New York (115)
North Carolina (80)
Northern California (222)
Ohio (19)
Pennsylvania (91)
South America (13)
South Carolina (2)
Southern California (208)
Tennessee (5)
Texas (60)
United States (1634)
Utah (25)
Virginia (3)
Washington State (40)
Wisconsin (4)
11,243 Results for "143".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
November 9, 2026
·
20 min read
Press Releases
Photys Therapeutics and Polymed Biopharmaceuticals Announce the Initiation of a Phase I Clinical Trial of PHT-776/HPB-143, an Oral IRAK4 PROTAC Degrader
August 13, 2026
·
3 min read
Press Releases
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
September 14, 2026
·
19 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
September 14, 2026
·
19 min read
Press Releases
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
·
7 min read
Press Releases
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
·
8 min read
Layoffs
Genentech Lays Off 143 Employees in South San Francisco Reshuffle
The downsizing comes after a year of workforce cuts and reorganization for Roche’s subsidiary.
June 11, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Analgesics Market Size to Exceed USD 143.42 Billion by 2034 Rising Chronic Pain and Advancements in Pain Relief Treatments
July 10, 2025
·
1 min read
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management.
May 15, 2024
·
2 min read
Press Releases
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
July 9, 2025
·
11 min read
1 of 1,125
Next
